Saliva EFIRM Liquid Biopsy

Wednesday, March 10, 2021: 10:30 AM - 11:05 AM

---

Description

Saliva is a bodily fluid that we produce ~600ml per day and harbors multiple omics constituents that can be harness non-invasive and painlessly for personalized and precision medicine is ideal for liquid biopsy applications. Yet PCR-based technologies cannot detect ctDNA in saliva samples whereas an emerging liquid biopsy platform “Electric Field Induced Release and Measurement (EFIRM)” can consistently detect ctDNA from NSCLC patients with actionable mutations in plasma and saliva with concordance of 95%+ with tissue/biopsy-based genotyping including early stage lesions. EFIRM detects ctDNA with a minimal footprint of 30bp, LOD of single digit copy number and conductance sensitivity inversely proportional to ctDNA fragment size, opposite to that for ddPCR detection. EFIRM provides accurate targeted detection that can assist clinical treatment decisions for the most common subtype of lung cancer, non-small cell lung cancer (NSCLC), with tyrosine kinase inhibitors (TKI) that can extend the disease progress free survival period of these patients. EFIRM can detection ctDNA at single copy level whereas ddPCR detects ctDNA a minimum of 30+ copy number. In addition EFIRM requires only 40 µl of sample volume, no sample processing, reaction time is 15min and can be performed at the point-of-care or high throughput reference lab using plasma or saliva. In two blinded independent clinical studies, EFIRM detects actionable EGFR mutations in NSCLC patients with >95% concordance with biopsy-based genotyping (1, 2). EFIRM detects ctDNA with a minimal footprint of 30bp, LOD of single digit copy number and conductance sensitivity inversely proportional to ctDNA fragment size, opposite to that for ddPCR detection.

---

Additional Info

Keywords: Please select up to 4 keywords ONLY:
Genomics, Proteomcs and Other 'Omics',Nucleic Acids